Posts by Noëlle Aubert

A novel algorithmic approach on cancer cells   Scientists at EPFL and UNIL have used a novel algorithmic approach on cancer cells to understand how changes in histone marks (H3K27ac) induce repositioning of chromatin regions in the cell nucleus, and described how modifications of local contacts between regulatory elements (enhancers and promoters) influence oncogene expression.…

CHF 5 million fundraising bNovate Technologies SA, a Swiss company specialised in industrial microbiology aiming at increasing the safety of drinking water, announces a Series B financing round of CHF 5 million. With its connected solutions allowing bacteria measurement in water in only 20 minutes, compared to several days with the current method, bNovate is…

Prize of CHF 50’000   EPFL scientists have developed a gel that can locally reinforce bones weakened by osteoporosis. The scientists entered their Flowbone startup in the Venture Kick competition for Swiss entrepreneurs and have just made it through the second round with a prize of CHF 50,000 in funding. “We plan to use this money…

Significant investments to expand its mammalian drug substance manufacturing facilities in Visp The Lonza‘s expansion in Visp (Valais, Switzerland) will see the development of a new large-scale mammalian drug substance manufacturing facility to expand capacity with six 20,000L bioreactors to meet increasing market demand in biologics. The new facility will have an area of approximately…

Strategic collaboration agreement between Swiss Biotech Center & Berna Biotech Pharma The Swiss biotech companies Berna Biotech Pharma Gmbh and Swiss Biotech Center SA announced that they have signed a strategic collaboration agreement for the development of a second generation vaccine against Covid-19. Berna Biotech and the Swiss Biotech Center will collaborate to bring a potential…

CHF 150,000 for RNA sequencing to boost biomedical research Lausanne-based Alithea Genomics, developing a novel technology that enables a high throughput library preparation for RNA sequencing, has been awarded CHF 150,000 from Venture Kick. The company will use the funds to advance and expand its BRB-seq kit offering. A fundamental challenge of biomedical research today…

The Lemanic region as a hub for Life Science innovation   Debiopharm a Swiss biopharmaceutical company based in Lausanne, announced the launch of the “Innovation DEbiopharm Academia Léman” (IDEAL) initiative with its first agreement signed with the University of Genva (UNIGE). Through IDEAL, Debiopharm will accelerate the maturation of academic research projects by offering expert advice and…

Commercialisation of the T50 Test to drive more efficient therapies for renal patients    Calciscon AG announced  the closing for its Series A financing, led by Yellowstone Holding, for CHF 2.5M. The proceeds of the financing enable the company to accelerate the introduction of its T50 test in routine clinical use in Europe, and prepare…

Building clinical research momentum with 500’000 CHF Tech Growth loan Clinical research and studies demonstrate Gondola Medical Technologies AMPS therapy’s effectiveness for people with neurological disease to move better and live better. The CHF 500’000 Tech Growth loan from the Fondation pour l’Innovation Technologique (FIT), supports Gondola Medical Technologies to develop their clinical research capabilities…